These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 34769060)

  • 1. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
    Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease.
    Badmus OO; Hinds TD; Stec DE
    Curr Hypertens Rep; 2023 Aug; 25(8):151-162. PubMed ID: 37191842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
    Zhou XD; Targher G; Byrne CD; Somers V; Kim SU; Chahal CAA; Wong VW; Cai J; Shapiro MD; Eslam M; Steg PG; Sung KC; Misra A; Li JJ; Brotons C; Huang Y; Papatheodoridis GV; Sun A; Yilmaz Y; Chan WK; Huang H; Méndez-Sánchez N; Alqahtani SA; Cortez-Pinto H; Lip GYH; de Knegt RJ; Ocama P; Romero-Gomez M; Fudim M; Sebastiani G; Son JW; Ryan JD; Ikonomidis I; Treeprasertsuk S; Pastori D; Lupsor-Platon M; Tilg H; Ghazinyan H; Boursier J; Hamaguchi M; Nguyen MH; Fan JG; Goh GB; Al Mahtab M; Hamid S; Perera N; George J; Zheng MH
    Hepatol Int; 2023 Aug; 17(4):773-791. PubMed ID: 37204656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.
    Meroni M; Longo M; Fracanzani AL; Dongiovanni P
    EBioMedicine; 2020 Jul; 57():102866. PubMed ID: 32629394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
    Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
    HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit.
    Fabris L; Campello E; Cadamuro M; Simioni P
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166763. PubMed ID: 37951510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review.
    Nasiri-Ansari N; Androutsakos T; Flessa CM; Kyrou I; Siasos G; Randeva HS; Kassi E; Papavassiliou AG
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
    Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
    Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microbial metabolome in metabolic-associated fatty liver disease.
    Li M; Rajani C; Zheng X; Jia W
    J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.